论文部分内容阅读
目的评价早期阿托伐他汀联合氯吡格雷治疗对不稳定型心绞痛(UAP)患者预后的影响。方法 126例UAP患者随机分为阿托伐他汀联合氯吡格雷治疗组和对照组,两组患者在常规吸氧、应用硝酸酯类、β受体阻滞剂、阿司匹林等传统治疗基础上,治疗组病例在发病24h之内口服阿托伐他汀10mg,以后每晚10mg睡前口服;氯吡格雷75mg早晨1次顿服,连用6个月,入院24h及治疗后8周抽空腹静脉血测定TC、LDL-C、HDL-C、hs-CRP,同时观察6个月内心血管事件。结果治疗组治疗后血TC、LDL-C、hs-CRP较治疗前明显下降(P<0.05),HDL-C较治疗前升高(P<0.01);对照组治疗前后观察指标无统计学意义(P>0.05)。治疗组6个月内心血管事件发生少于对照组,有统计学意义(P<0.05),脑卒中及心源性猝死两组间无统计学意义(P>0.05)。结论早期应用阿托伐他汀联合氯吡格雷治疗不稳定型心绞痛能明显改善患者预后。
Objective To evaluate the effect of early atorvastatin combined with clopidogrel on the prognosis of patients with unstable angina (UAP). Methods 126 cases of UAP patients were randomly divided into atorvastatin combined with clopidogrel treatment group and control group, two groups of patients in the conventional oxygen, nitrates, β-blockers, aspirin and other traditional treatment based on the treatment Group of patients within 24 hours of onset of oral atorvastatin 10mg, after 10mg night before bedtime oral; clopidogrel 75mg morning 1 Dayton service, once every 6 months, admission 24h and 8 weeks after treatment, fasting blood TC , LDL-C, HDL-C, hs-CRP, and observed cardiovascular events within 6 months. Results The levels of TC, LDL-C and hs-CRP in the treatment group were significantly lower than those before treatment (P <0.05), while the levels of HDL-C in the treatment group were significantly higher than those before treatment (P <0.01) (P> 0.05). The incidence of cardiovascular events within 6 months in the treatment group was less than that in the control group, with statistical significance (P <0.05). There was no significant difference between the two groups in stroke and sudden cardiac death (P> 0.05). Conclusion Early application of atorvastatin combined with clopidogrel in the treatment of unstable angina pectoris can significantly improve the prognosis of patients.